Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."
This patent covers compounds including clavulanic acid and moxalactam for the treatment of neurological disorders such as depression, anxiety, dementia, Alzheimer's disease and Parkinson's disease, as well as their use and pharmaceutical formulation.
Rick Soni, President of Rexahn, noted, "Obtaining this European patent coverage for clavulanic acid and moxalactam broadens and strengthens our CNS-related portfolio, which includes Serdaxin®, currently in Phase II clinical trials."
International team releases recommendations for AI use in neuro-oncology